#AS­CO21: Gilead­'s Trodelvy reads out new sub­group da­ta show­ing ben­e­fit in ear­li­er-line TNBC pa­tients

With As­traZeneca and Dai­ichi sniff­ing at its trail, Gilead has worked hard to hold an ad­van­tage for ADC Trodelvy in par­tic­u­lar­ly hard-to-treat breast can­cer pa­tients. Now, the drug­mak­er is read­ing out more late-stage da­ta show­ing some ben­e­fit in ear­li­er-line pa­tients, and it could help carve a path for­ward to a big­ger mar­ket share.

Gilead’s Trodelvy ex­tend­ed sur­vival in a sub­group analy­sis of re­lapsed or re­frac­to­ry triple-neg­a­tive breast can­cer pa­tients in the sec­ond line, a pos­i­tive sign Gilead hopes could spell ear­li­er lines of ther­a­py for its TROP2-di­rect­ed ADC, ac­cord­ing to da­ta from the Phase III AS­CENT study set to be pre­sent­ed at this week­end’s #AS­CO21.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER